SHANGHAI, MONTREAL and SALT LAKE CITY, Nov. 3, 2016 /PRNewswire/ - Phagelux, Inc., a biotechnology company focused on the development and commercialization of novel phage and lysin antibacterial products and solutions, announces the appointment of Dr. Rong Chen as the company's Global Chief Medical Officer.
Dr. Chen has more than 25 years of experience in pharmaceutical drug development, including extensive knowledge of global clinical trials and regulatory approvals. Immediately prior to joining Phagelux, Dr. Chen was the Chief Medical Officer at CASI Pharmaceuticals (NASDAQ – CASI), where he was responsible for global product development and global product registrations. Preceding that, Dr. Chen held positions of increasing responsibility within GSK. During his career, Dr. Chen also worked at Bayer and Sanofi as the Asia Pacific/China Medical Director for each organization respectively. Early in his career Dr. Chen worked at the TGA, the Australia regulatory authority. Dr. Chen received an MD from the Shandong Medical University and a Ph.D. from the Royal Adelaide Hospital.
At Phagelux, Dr. Chen will be responsible for global drug development and global regulatory approvals. In addition, as part of the management team, Dr. Chen will be instrumental in determining and implementing a product development strategy and will additionally be involved in certain business development activities.
Mark Engel, CEO of Phagelux says about the appointment: "We are very excited to have Rong Chen join the Phagelux team. His wealth of experience in all aspects of drug development will immediately and positively impact our company, particularly in regard to our goal to bring multiple products into Phase I clinical trials in 2017. Equally importantly, Rong Chen has extensive antibacterial experience that will be pivotal to our strategic planning over the next few years. In sum, adding Rong Chen to our management team is an important step in the globalization of our company."
About Phagelux, Inc.
Phagelux utilizes phages, lysins and other biologics and related delivery technologies to create antibacterial products and solutions. Phagelux is headquartered in Shanghai with laboratories in China and North America and manufacturing facilities in the United States and China. Phagelux has both HumanHealth and AgriHealth divisions.
SOURCE Phagelux, Inc.